nanomicellular cyclosporine 0.09% + Lifitegrast

ApprovedUNKNOWN
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Dry Eye

Conditions

Dry Eye

Trial Timeline

Feb 1, 2020 โ†’ Dec 1, 2022

About nanomicellular cyclosporine 0.09% + Lifitegrast

nanomicellular cyclosporine 0.09% + Lifitegrast is a approved stage product being developed by Sun Pharmaceutical for Dry Eye. The current trial status is unknown. This product is registered under clinical trial identifier NCT04172961. Target conditions include Dry Eye.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04172961ApprovedUNKNOWN

Competing Products

20 competing products in Dry Eye

See all competitors